ClinicalTrials.gg

Program

RC148

A development code. Also written as “RC148 plus Telisotuzumab adizutecan”, “RC118(Dose 1) plus RC148(Dose 1)” and “RC118(Dose 1) plus RC148(Dose 2)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Colonic Neoplasms · Breast Neoplasms, led by RemeGen.

Furthest: phase 3, since Feb 10, 20268 company-led studies, 8 open or runningNext primary completion: May 12, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen88 open or runningphase 3since Feb 10, 2026Aug 18, 2023May 12, 2027phase 3 · NCT07462143
  • Named in abbvie’s own pipeline as ABBV-1480 (RC148), phase 3, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2023First study: phase 2 study in Solid TumorFirst studyNCT06016062 · 221 planned · China
  2. Oct 13, 2024Phase 2 study in Breast NeoplasmsNCT06642545 · 40 planned · China
  3. Mar 5, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06883630 · 121 enrolled · China
  4. Feb 10, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07416474 · 574 planned · China
  5. Mar 4, 2026Phase 3 study in Colonic NeoplasmsNCT07462143 · 80 planned · China
  6. Sep 8, 2026Phase 3 study in Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic AlterationsNCT07829549 · 540 planned · China
  7. Oct 12, 2026Phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyNCT07895355 · 412 planned · China
  8. Nov 1, 2026Phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07935369 · 680 planned · China

Ahead

  1. May 12, 2027Primary completion: phase 3 study in Colonic NeoplasmsNCT07462143
  2. Dec 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07416474
  3. Jul 2028Primary completion: phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyNCT07895355
  4. Apr 30, 2030Primary completion: phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07935369

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07935369Advanced Gastric or Gastroesophageal Junction Adenocarcinoma · China3Not yet recruitingApr 30, 2030680
NCT07895355Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy · China2Not yet recruitingJul 2028412
NCT07829549Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations · China3RecruitingApr 2031540
NCT07462143Colonic Neoplasms · China3RecruitingMay 12, 202780
NCT07416474Carcinoma, Non-Small-Cell Lung · China3RecruitingDec 31, 2027574
NCT06883630Carcinoma, Non-Small-Cell Lung · China1Active, not recruitingAug 31, 2026121
NCT06642545Breast Neoplasms · China2RecruitingOct 1, 202640
NCT06016062Solid Tumor · China2RecruitingDec 31, 2025221

How it is read

Names in the registry

  • “RC148 plus Telisotuzumab adizutecan”, 4 entries
  • “RC148”, 2 entries
  • “RC118(Dose 1) plus RC148(Dose 1)”, 1 entry
  • “RC118(Dose 1) plus RC148(Dose 2)”, 1 entry
  • “RC118(Dose 2) plus RC148(Dose 1)”, 1 entry

Codes read as this program: RC148.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.